ABSTRACT
The emergence of the novel coronavirus SARS-CoV-2 has significantly impacted the world's population, disrupting healthcare systems around the globe and leading to human and material losses. While different vaccines have been approved in record time, there continues to be a high number of daily new cases, and patients face a wide range of presentations of the disease, from asymptomatic to potentially fatal. Therefore, the search for therapeutic agents that can aid in the management and control of the disease has become one of the main goals for researchers and clinicians. As an inflammatory disease, targets for the treatment of COVID-19 have largely involved the immune system. Inflammation has also been associated with mental health disorders, and studies have shown the potential involvement of inflammatory pathways in the pathophysiology of depression. As a consequence, the hypothesis of using antidepressants and other psychotropics for the treatment of COVID-19 has emerged. In this review, we aim to summarize the molecular pathways that could be involved as well as the emergent evidence that has been reported by studies performed since the appearance of SARS-CoV-2 in 2019. While it has been observed that there are potential therapeutic pathways for the use of antidepressants in the treatment of COVID-19, additional studies are needed to evaluate the feasibility, safety, and efficacy of psychotropics in this disease.Copyright © 2023 Bentham Science Publishers.
ABSTRACT
The SARS-CoV-2 infection has become as a worldwide public health emergency. It exhibits a variety of clinical presentations, ranging from benign to acute respiratory distress syndrome, systemic involvement, and multiorganic failure. The severity of the clinical picture depends on host and virus biological features and the presence of comorbidities such as chronic kidney disease. In addition, the interaction between the virus, angiotensin-converting enzyme 2, and the exacerbated immune response could lead to the development of acute kidney injury. However, the implications of SARS-CoV-2 infection on renal cells, the prognosis of patients with chronic kidney disease, and the long-term behavior of renal function are not entirely understood. This review aims to explore the role of SARS-CoV-2 in acute and chronic kidney disease and the possible pathogenic mechanisms of renal involvement.
Subject(s)
Acute Kidney Injury , COVID-19 , Renal Insufficiency, Chronic , Acute Kidney Injury/etiology , Humans , SARS-CoV-2ABSTRACT
By the end of 2019 emerged a cluster of pneumonia that was caused by a novel SARS-CoV-2 virus. The disease, subsequently named COVID-19, has a wide range of signs and symptoms, including fever, respiratory and gastrointestinal manifestations, and kidney disease that can evolve to a nutritional imbalance through direct and indirect mechanisms. Moreover, the prognosis of COVID-19 could worsen in high-risk populations like kidney disease patients, given their depressed immunity and impaired nutritional state. Therefore, previous reports suggest prioritizing a nutritional approach in these patients, adjusting for individual dietary needs. Thus, we aim to explore the current knowledge about the clinical and nutritional implications of patients with COVID-19 who develop acute or chronic kidney disease, highlighting proposed dietary recommendations in this group of patients.